166.78 0.00 (0.00%)
After hours: 4:54PM EDT
|Bid||139.53 x 400|
|Ask||185.00 x 100|
|Day's Range||164.67 - 167.78|
|52 Week Range||131.67 - 170.00|
|PE Ratio (TTM)||62.23|
|Earnings Date||Apr 26, 2018|
|Forward Dividend & Yield||1.88 (1.19%)|
|1y Target Est||174.54|
, the shipping broker, is heading for its worst day on record after warning that 2018 profit will be materially below last year. Panmure Gordon cut its 2018 underlying earnings forecast for Clarkson by 24 per cent to 108p a share but left long-term forecasts unchanged. “Given the bullish outlook for shipping markets presented by Clarkson at the results [in March], this warning is a surprise.
Stryker Corporation’s (NYSE:SYK) most recent return on equity was a substandard 10.22% relative to its industry performance of 10.89% over the past year. An investor may attribute an inferior ROERead More...
Zacks.com highlights: Zebra Technologies, Stryker, Progressive, Interpublic Group and CBRE Group
Considering the ageing population, changing market dynamics, upbeat consumer sentiment and increased business investments, the Medical-Device sector appears to be in pink of health.
Kalamazoo, Michigan - April 3, 2018 - Stryker Corporation (NYSE:SYK) announced today that after 30 years of distinguished service, Lonny Carpenter , Group President, Global Quality and Business Operations ...
3D printing lends a competitive edge to medical device manufacturers by enhancing efficiency and cutting down on processing time.
In this article, I will take a look at Stryker Corporation’s (NYSE:SYK) most recent earnings update (31 December 2017) and compare these latest figures against its performance over the pastRead More...
Kalamazoo, Michigan - March 22, 2018 - Stryker Corporation (NYSE:SYK) announced that it will host a conference call on Thursday, April 26, 2018 at 4:30 p.m., Eastern Time, to discuss the Company`s operating ...
The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Over the last one-month, outflows of investor capital in ETFs holding SYK totaled $2.48 billion.
Haemonetics (HAE) expects its transfusion management business to grow at a compound annual growth rate (or CAGR) in the low to mid teens. Haemonetics has planned to opt for a key account strategy. The company aims to strengthen its worldwide presence by expanding its global sales team and partnering with other software vendors and players in this segment, like Helmer.
Kalamazoo, Michigan - March 21, 2018 - Stryker Corporation (NYSE:SYK) announced that its 2018 Annual Meeting of Shareholders is scheduled as follows: May 2, 2018 - 2:00 p.m. Eastern Time Radisson Plaza ...
Haemonetics (HAE) is focused on initiating the commercial launch of its innovative NexSys PCS device coupled with its embedded firmware, NexLynk DMS, in 2H18. Although the combination of the NexSys PCS device and the NexLynk software is designed to result in a completely integrated and optimal bidirectional system, NexSys PCS supports an open architecture and can work with any other donor management software (or DMS). NexLynk software, however, has been designed to work optimally with NexSys PCS, and it thus eliminates the need for the translation of data between the device and the software.
In fiscal 2017, Haemonetics (HAE) earned almost 46% of its total revenue from its plasma franchise. The company has earned ~48.4% of its total revenue from its plasma franchise YTD (year-to-date) in fiscal 2018. Approximately 91% of the plasma segment’s total revenue in fiscal 2017 was attributable to the sale of disposables.
In fiscal 3Q18, Haemonetics (HAE) reported revenue of close to $113.1 million, a YoY (year-over-year) rise of ~4.1%. Haemonetics has earned revenue of nearly $324.4 million from the sale of its products in the plasma franchise YTD (year-to-date) in fiscal 2018, which reflects a YoY rise of ~4.7%. The franchise has reported organic revenue growth of close to 6% YTD in fiscal 2018, and it’s expected to continue witnessing robust growth owing to solid demand for drugs based on human plasma.
On its fiscal 3Q18 earnings conference call, Haemonetics (HAE) increased the guidance for its fiscal 2018 adjusted EPS (earnings per share) by ~$0.12 to the range $1.80–$1.90. Haemonetics has calculated this EPS guidance by assuming a positive impact from its overperformance in fiscal 3Q18 and a negative impact from its anticipated investments in fiscal 4Q18. Excluding the impact of its restructuring and turnaround expenses, the company expects $125 million worth of free cash flow in fiscal 2018.
Haemonetics (HAE) expects to report fiscal 2018 revenue in line with what it witnessed in fiscal 2017. The company also expects to witness 6% YoY revenue growth in its hospital business, lower than its previously projected revenue growth rate range of 7%–10%. Haemonetics, however, expects its blood center business to report a 7% YoY fall in fiscal 2018 revenue, which is at the lower end of its expectation of a fall of 7%–10%.